BioSpace News Archive

Test Measures Key Biomarker Associated with Neuronal Damage; Assists in Diagnosis of Diseases Including Multiple Sclerosis, Alzheimer’s, Parkinson’s and Concussions.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer (“CEO”) and a member of the Company’s Board of Directors.

Due to the COVID pandemic, work for the FDA approval of the tinniwell was stopped at the beginning of 2021. This has now been resumed and Chief Medical Officer Thomas Rauterkus has been commissioned to manage the project.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial market opens on August 11, 2022.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022.

iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company will showcase and demonstrate the complete portfolio of its Breast AI solutions, including ProFound AI®, PowerLook® Density Assessment , and ProFound AI® Risk , in booth #AI-20 at the European Congress of Radiology (ECR), July 13-17 in Vienna.

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, announced favorable topline results from its recently completed SEQURUS-1 study.

The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of approximately $50,000 each to five community-based organizations (CBOs) as recipients of the inaugural Access to Care Empowerment for Sickle Cell (ACE) Grant Program.

Amarin Corporation plc (NASDAQ: AMRN) today announced that NICE has issued its final guidance recommending VAZKEPA® (icosapent ethyl) for reimbursement and use across the National Health Service (NHS) in England and Wales to help reduce the risk of major CV events in high-risk statin-treated patients with eCVD, at a price of £144.21 per 120 soft capsules (i.e. 30 day supply; the equivalent of approximately 171 EUR or 172 USD*).

Smith+Nephew (LSE: SN) (NYSE: SNN), the global medical technology company, today announces a robust line-up featuring several of its advanced joint repair solutions and a wide array of educational activities during the 2022 American Orthopaedic Society for Sport Medicine (AOSSM) Annual Meeting being held in Colorado Springs July 13-17.